Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights Regeneron, Vertex, Intercept Pharmaceuticals, and Biohaven Pharmaceutical

Read MoreHide Full Article

For Immediate Release

Chicago, IL – May 13, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Regeneron (REGN - Free Report) , Vertex (VRTX - Free Report) , Intercept Pharmaceuticals, Inc. (ICPT - Free Report) , Biohaven Pharmaceutical Holding Company Ltd. (BHVN - Free Report) .

Here are highlights from Thursday’s Analyst Blog:

Biotech Stock Roundup: Q1 Earnings Edition

The biotech sector has been in the spotlight in the past week with earnings updates from most of the bigwigs. Other important pipeline and regulatory updates were also in focus.

Recap of the Week's Most Important Stories:

Earnings Update from Regeneron, Vertex: Regeneron posted better-than-expected first-quarter 2022 results, beating on both earnings and sales driven by strong growth in Eylea and Dupixent.  First-quarter earnings of $11.49 per share comfortably beat the Zacks Consensus Estimate of $9.37. Earnings jumped 16% from the year-ago quarter due to higher sales. Total revenues in the reported quarter were up 17% year over year to $2.9 billion and beat the Zacks Consensus Estimate of $2.71 billion.

Solid demand for Eylea and Dupixent maintained momentum for the company. However, sales from REGEN-COV took a hit due to the regulatory update. Excluding REGEN-COV (a cocktail of two monoclonal antibodies — casirivimab and imdevimab) for COVID-19, sales increased 25%.

Vertex's earnings per share of $3.52 missed the Zacks Consensus Estimate of $3.60. Nevertheless, the bottom line rose 18% year over year on higher revenues. Strong cystic fibrosis product revenues led to higher earnings in the reported quarter. Revenues of $2.10 billion surpassed the Zacks Consensus Estimate of $2.08 billion. Total product revenues rose 22% year over year, primarily driven by higher sales of Trikafta (marketed as Kaftrio in Europe).

Vertex carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Updates from InterceptIntercept Pharmaceuticals, Inc. entered into an agreement to sell certain foreign subsidiaries and rights regarding its international operations, including a license to commercialize lead drug Ocaliva  (obeticholic acid or OCA) outside of the United States to Advanz Pharma for the indication of primary biliary cholangitis (PBC).

Intercept will receive an upfront payment of $405 million and an additional $45 million from Advanz Pharma contingent upon receipt of an extension of pediatric orphan exclusivity in Europe. Intercept will receive royalties on any future net sales of obeticholic acid in NASH outside of the United States, if Advanz Pharma pursues marketing authorization for this indication in ex-U.S. regions.

The company will also continue to be responsible for the manufacturing and supply of obeticholic acid globally. Advanz Pharma will be responsible for packaging, distribution and commercialization of the therapy in all markets outside the United States.

Intercept also announced that the first patient has been dosed in a phase II study evaluating a fixed-dose combination of OCA and bezafibrate (BZF) for the treatment of patients with PBC who have not achieved an adequate biochemical response to ursodeoxycholic acid.

Biohaven Surges on Pfizer Deal:  Shares of Biohaven Pharmaceutical Holding Company Ltd. surged significantly after Pfizer announced that it will acquire the former for $11.6 billion in cash. Per the terms, Pfizer will acquire all outstanding shares of Biohaven not already owned by it for $148.50 per share in cash.

Biohaven common shareholders, including Pfizer, will also receive 0.5 of a share of New Biohaven, a new publicly traded company that will retain the former's non-CGRP development stage pipeline compounds, per Biohaven common share. The price of $148.50 represents a premium of approximately 33% to Biohaven's volume-weighted average selling price of $111.70 over the three months prior to the transaction's announcement.

Performance

Medical - Biomedical and Genetics Industry 5YR % Return

The Nasdaq Biotechnology Index has lost 13.18% in the past five trading sessions. Among the biotech giants, Moderna has declined 20.39% during the period. Over the past six months, shares of Moderna have lost 45.34%. (See the last biotech stock roundup here: Biotech Stock Roundup: BIIB & GILD's Earnings Update, VRTX Down on Regulatory News)

What's Next in Biotech?

Stay tuned for more pipeline and regulatory updates.

Why Haven't You Looked at Zacks' Top Stocks?

Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.

See Stocks Free >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                                      

https://www.zacks.com                                                 

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.